Frost Radar Report: Antibody-Drug Conjugate Contract Development & Manufacturing Organizations
Published on March 17, 2026
Abzena is recognized as a technology-forward, innovative CDMO in the Frost Radar™: ADC Contract Development and Manufacturing Report, 2025
In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research firm Frost & Sullivan independently evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth.
Download the report to discover what to look for in an ADC CDMO partner and learn more about:
- How Abzena’s proprietary ThioBridge® site-specific conjugation platform improves the design & delivery of ADCs.
- How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs.
- How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors
- How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.
Download the Report
The post Frost Radar Report: Antibody-Drug Conjugate Contract Development & Manufacturing Organizations appeared first on Abzena.